ERBB2 and breast carcinoma: In conclusion, our findings support the use of maintenance anti-HER2 treatment in HER2+ breast cancer sensitive to anti-HER2 therapies, and warrant further research into exploiting molecular subtypes changes (i.e., HER2-E to Luminal) to improve patient outcomes.